Abstract
One of the major improvements in Cystic Fibrosis (CF) patients (pts) who started the commercial triple combination elexacaftor/texacaftor/ivacaftor (ETI) is the nutritional status (NS). A consistent increase in Fat Mass (FM) is linked to a high risk of developing obesity and cardiovascular disease. In Ancona CF Centre NS was monitored at fixed times (T0, T1, T3, T6, T12) in pts on ETI.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.